ASX:TLXBiotechs
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Strong Guidance And Gozellix Medicare Momentum
Why Telix’s latest guidance is attracting fresh attention
Telix Pharmaceuticals (ASX:TLX) is back on many investors’ radar after the company issued 2026 revenue guidance of US$950 million to US$970 million and highlighted strong 2025 results supported by Gozellix uptake and Medicare reimbursement.
See our latest analysis for Telix Pharmaceuticals.
That guidance and the recent Gozellix and TLX101 Px updates have arrived after a volatile spell, with a 1 day share price return of 10.87% and a 1...